Surrozen, Inc./DE Operating Lease, Right-of-Use Asset, Amortization Expense
Surrozen, Inc./DE (SRZN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $900.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- Surrozen, Inc./DE operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $450.00K, a 0.00% change year-over-year.
- Surrozen, Inc./DE operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $450.00K, a 0.22% decline year-over-year.
- Surrozen, Inc./DE operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $450.00K, a 0.00% change year-over-year.
- Surrozen, Inc./DE operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $450.00K, a 25.70% increase year-over-year.
- Surrozen, Inc./DE operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.80M, a 18.33% increase from fiscal 2024.
- Surrozen, Inc./DE operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.52M, a 19.56% increase from fiscal 2023.
- Surrozen, Inc./DE operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.27M, a 3.12% decline from fiscal 2022.
- Surrozen, Inc./DE operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.31M, a 6.74% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $450.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $900.00K 10-Q · filed 2026-08-06 | $1.35M derived: sum of 3 quarters · filed 2026-08-06 | $1.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $450.00K 10-Q · filed 2026-05-06 | $900.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.35M derived: sum of 3 quarters · filed 2026-05-06 | $1.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $900.00K derived: sum of 2 quarters · filed 2026-03-23 | $1.35M derived: sum of 3 quarters · filed 2026-08-06 | $1.80M 10-K · filed 2026-03-23 |
| 2025-09-30 | $450.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $900.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.35M 10-Q · filed 2025-11-07 | $1.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $450.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $901.00K 10-Q · filed 2026-08-06 | $1.35M derived: sum of 3 quarters · filed 2026-08-06 | $1.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $451.00K 10-Q · filed 2026-05-06 | $901.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.26M derived: sum of 3 quarters · filed 2026-05-06 | $1.62M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $808.00K derived: sum of 2 quarters · filed 2026-03-23 | $1.17M derived: sum of 3 quarters · filed 2026-03-23 | $1.52M 10-K · filed 2026-03-23 |
| 2024-09-30 | $358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $715.00K derived: sum of 2 quarters · filed 2025-11-07 | $1.07M 10-Q · filed 2025-11-07 | $1.41M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $357.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $714.00K 10-Q · filed 2025-08-08 | $1.05M derived: sum of 3 quarters · filed 2025-08-08 | $1.37M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $357.00K 10-Q · filed 2025-05-09 | $693.00K derived: sum of 2 quarters · filed 2025-05-09 | $1.02M derived: sum of 3 quarters · filed 2025-05-09 | $1.33M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $336.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $660.00K derived: sum of 2 quarters · filed 2025-03-31 | $972.00K derived: sum of 3 quarters · filed 2025-03-31 | $1.27M 10-K · filed 2025-03-31 |
| 2023-09-30 | $324.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $636.00K derived: sum of 2 quarters · filed 2024-11-06 | $937.00K 10-Q · filed 2024-11-06 | $1.23M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $312.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $613.00K 10-Q · filed 2024-08-12 | $903.00K derived: sum of 3 quarters · filed 2024-08-12 | $1.18M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $301.00K 10-Q · filed 2024-05-08 | $591.00K derived: sum of 2 quarters · filed 2024-05-08 | $870.00K derived: sum of 3 quarters · filed 2024-05-08 | $1.25M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $290.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | $569.00K derived: sum of 2 quarters · filed 2024-04-10 | $947.00K derived: sum of 3 quarters · filed 2024-04-10 | $1.31M 10-K · filed 2024-04-10 |
| 2022-09-30 | $279.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $657.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.02M 10-Q · filed 2023-11-08 | $1.30M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $378.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $745.00K 10-Q · filed 2023-08-09 | $1.02M derived: sum of 3 quarters · filed 2023-08-09 | $1.35M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $367.00K 10-Q · filed 2023-05-10 | $640.00K derived: sum of 2 quarters · filed 2023-05-10 | $970.00K derived: sum of 3 quarters · filed 2023-05-10 | $1.29M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $603.00K derived: sum of 2 quarters · filed 2023-03-31 | $922.00K derived: sum of 3 quarters · filed 2023-03-31 | $1.23M 10-K · filed 2023-03-31 |
| 2021-09-30 | $330.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $649.00K derived: sum of 2 quarters · filed 2022-11-14 | $958.00K 10-Q · filed 2022-11-14 | $1.26M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $628.00K 10-Q · filed 2022-08-11 | $927.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $309.00K 10-Q · filed 2022-05-11 | $608.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $299.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $992.00K 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $693.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |